

1. (amended) A recombinant adeno-associated virus vector, which comprises:

a) at least a portion of the adeno-associated virus genome;

b) at least one eukaryotic based *cis*-acting regulatory sequence; and

c) at least one eukaryotic based nucleic acid sequence that encodes a wildtype [therapeutic] gene product, said virus vector having the property of regulating cell specific expression of said nucleic acid sequence or nucleic acid sequences upon stable transduction of a target mammalian cell.

27. A recombinant adeno-associated virus vector, which comprises:

a) at least a portion of the adeno-associated virus genome;

b) a eukaryotic based *cis*-acting regulatory sequence; and

c) a eukaryotic based nucleic acid sequence that encodes a wildtype [therapeutic] gene product, said virus vector having the property of regulating cell specific expression of said nucleic acid sequence or nucleic acid sequences upon stable transduction of a human hematopoietic cell.

Add the following new Claims ~~40-44~~

-- (new) <sup>46</sup>40. The recombinant adeno-associated virus of Claim 1 in which the portion of the adeno-associated virus

genome comprises at least those nucleotide sequences encoding the inverted terminal repeats.

83  
Sub PG  
cont

(new) <sup>47</sup> 40. The adeno-associated virus of Claim 27 is which the portion of the adeno-associated virus genome comprises at least those nucleotide sequences encoding the inverted terminal repeats.---

#### REMARKS

Claims 1 and 27 have been amended to recite that the recombinant adeno-associated viral vectors encode a therapeutic gene product as opposed to a therapeutic protein. This amendment does not represent new matter and its entry is requested simply to clarify what is meant by the claimed invention. For reasons detailed below, Applicants request that the rejections be withdrawn and pending claims allowed to issue.

#### 1. THE INVENTION

The present invention relates to recombinant adeno-associated virus vectors for gene delivery and regulated tissue specific expression in a host. The vectors of the invention contain a mammalian gene of interest, cis-acting regulatory and promoter elements of the gene of interest and an adeno-associated virus vector comprising the nucleotide sequences encoding the minimal signals of the inverted terminal repeat required for replication, encapsidation, and integration of the viral vector, engineered in such a way that